Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia
Authors:
- Marc J.T.M. MolMMMarc J.T.M. Mol
- D. Willem ErkelensDED. Willem Erkelens
- Jan A. Gevers LeuvenJLJan A. Gevers Leuven
- Jan A. SchoutenJSJan A. Schouten
- Anton F.H. StalenhoefASAnton F.H. Stalenhoef
- 1 February 1988
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 69 (2-3) , 131-137
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II1986
- SYNVINOLIN IN HYPERCHOLESTEROLAEMIAThe Lancet, 1986
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986
- A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemiaAtherosclerosis, 1985
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.Journal of Clinical Investigation, 1982
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Enzymatische Bestimmung des Gesamt-Cholesterins im SerumClinical Chemistry and Laboratory Medicine (CCLM), 1974
- RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATESThe Lancet, 1969